Report Details:
15 Companies Covered
90 Pages
Market Research Future (MRFR) has updated the report on the global ADME Toxicology Testing Market, which was valued at USD 7.12 billion in 2025, and is projected to reach USD 7.79 billion in 2026. USD 17.48 billion by 2035, registering a compound annual growth rate (CAGR) of 9.38% during the forecast period (2026-2035).
FDA’s Modernization Act 2.0, which officially accepts non-animal testing data for IND submissions, rapid advances in AI and machine learning for predicting drug metabolism and a surge in global pharmaceutical R&D spending that crossed USD 260 billion in 2024 are transforming the market.
Market Overview
ADME toxicology testing has become a strategic imperative for global pharmaceutical and biotech companies seeking to accelerate drug development timelines while ensuring safety and regulatory compliance. Regulatory modernization, AI-powered prediction platforms and state-of-the-art cell-based technologies are converging to fundamentally change the way sponsors perform preclinical safety profiling, creating a fertile growth environment for CROs and technology providers throughout the world.
North America holds around 38% of the global market share, supported by the presence of top-20 pharma companies’ headquarters and considerable NIH research funding. Europe has approximately a 27% share of the global market. In comparison, Asia-Pacific is the fastest-growing region with a CAGR of 11.2% due to contract research capacity expansion and regulatory harmonization with ICH guidelines.
Key Market Trends & Growth Drivers
Regulatory Modernization: Unlocking Non-Animal Testing: The FDA Modernization Act 2.0 eliminated the federal requirement for animal testing in drug approval, and by mid-2024 the agency had accepted data from alternative methods in more than 35 new drug submissions, shifting an estimated USD 800 million per year in preclinical spending from animals to cell-based and computational platforms.
AI and Machine Learning in Drug Metabolism Prediction: Pharmaceutical sponsors are rapidly embedding AI models into metabolic stability testing workflows to predict clearance rates, CYP450 interactions and off-target toxicity prior to wet-lab confirmation. In late 2023, Insilico Medicine completed an out-licensing deal with Exelixis with upfront payments of USD 80 million and, in early 2024, a cooperation with Menarini for more than USD 500 million.
Oncology and Advanced Therapy Pipelines: Oncology remains the greatest therapeutic focus area, accounting for almost 41% of all active clinical trials globally. Advanced modalities such as cell and gene therapies introduce complex pharmacokinetic mechanisms that require highly specialized, bespoke ADME characterization protocols.
CRO Outsourcing and Capacity Expansion: Contract research organizations are gaining a larger share of the global preclinical industry, which is valued at over USD 6.8 billion. Asia-Pacific CROs have answered this demand with major infrastructure expansions, with WuXi AppTec undertaking capital expenditure programs of over USD 1 billion per year.
ESG-Driven Transition Away from Animal Models: Animal use reduction targets are a component of ESG disclosures for more than 60% of top-20 pharma companies, and institutional investors with assets under management exceeding USD 15 trillion have identified animal testing practices as a material governance issue, underpinning long-term demand for human-relevant in vitro and in silico platforms.
Market Segmentation Insights
By Technology: Cell Culture Technology accounted for the largest share of almost 44% of the market. The growth of the segment is driven by the increasing adoption of organ-on-chip and 3D culture technologies in preclinical applications.
By Method: Real-time pharmacokinetics safety profiling accelerates in oncology programs. Molecular Imaging Technology is the fastest-growing segment at 10.6% CAGR. Cellular Assay holds the dominant position in the market by Method with around a 36% share due to its widespread application in hepatotoxicity screening and metabolic stability testing.
By Application: By Application, Systemic Toxicity Testing is anticipated to command the biggest market of ~41% in 2025, since it is a uniform regulatory need across all treatment fields. Renal Toxicity Testing is the fastest-growing application with a CAGR of 10.3% driven by increased nephrotoxicity concerns in oncology pipelines.
By End User: Pharmaceutical and biotechnology businesses are the majority shareholders with around 58% in 2025, performing most of the drug absorption testing and pharmacokinetics safety profiling in-house for their proprietary pipelines. The fastest-growing end-user segment is Contract Research Organizations with 11.4% CAGR, indicating a trend in the industry to outsource preclinical services.
Regional Landscape
North America -- Technology and Regulatory Leader
North America holds the largest share in the ADME Toxicology Testing Market, accounting for around 38% of global market share. Growth in the region is spurred by the FDA Modernization Act 2.0, the headquarters of eight of the world’s ten largest pharmaceutical corporations and more than USD 48 billion in annual research funding from the NIH. The FDA’s NCATS division is actively supporting programs that validate in vitro toxicity assays for use in regulatory submissions, which further increases the domestic demand for advanced hepatotoxicity screening methods. The US dominates the area, with Canada’s life sciences corridor attracting preclinical CRO investment and Mexico benefiting from nearshoring trends.
Europe -- Emerging Regulatory Pathways
Europe is home to about 27% of the global market and, according to the EMA’s Regulatory Science Strategy for 2023, specific focus is being placed on non-animal approaches, with EUR 95 million invested in Horizon Europe for the development of alternative testing methods. Germany is leading the regional adoption, anchored by Bayer, Boehringer Ingelheim and Merck KGaA's preclinical operations. The UK, France and Italy are next, with the UK’s MHRA being a fast-follower regulator adopting pharmacokinetics safety profiling data from approved in silico platforms.
Asia-Pacific -- Fastest-Growing CRO Hub
Asia-Pacific is the fastest-expanding market with 11.2% CAGR, driven by China’s NMPA regulatory overhaul and India’s Biopharma SHAKTI plan deploying INR 10,000 crores over five years. China now comprises an estimated 28% of all drug absorption testing studies outsourced by Western sponsors worldwide. At the same time, India's Hyderabad-Bangalore corridor has emerged as a world centre for in vitro toxicity assays.
Middle East and Africa -- Untapped Market Potential
Increasing proportion of global market in the Middle East and Africa area, with growth being led by Saudi Arabia's Vision 2030 program allocating over USD 6 billion to modernize the health system, including preclinical research facilities. The UAE’s positioning as a regional life sciences hub continues to attract CRO satellite operations, and SAHPRA reform and academic toxicology research in South Africa contribute to regional development.
Competitive Landscape
The ADME Toxicology Testing Market is highly consolidated, with the top five players accounting for an estimated 30--36% of global revenues. The Herfindahl-Hirschman Index is in the 800-1,200 range, indicating a moderately competitive structure in which large CROs and diversified life- science firms compete with specialized in silico and organ-on-chip innovators. The key participants are Charles River Laboratories, Eurofins Scientific, Covance (LabCorp Drug Development), WuXi AppTec, Evotec, Pharmaron, Cyprotex, Absorption Systems, Simulations Plus and CN-Bio Innovations.
Future Outlook
The ADME Toxicology Testing Market is expected to be reshaped by 2035 with the increasing commercialization of organ-on-chip on a large scale, AI-as-a-Service platforms for in silico ADME prediction, and a growing penetration in the emerging markets of Asia-Pacific, the Middle East, and Africa. Companies that focus on regulatory-validated non-animal platforms, integrated data ecosystems for pharmacokinetics safety profiling, and AI-augmented preclinical decision-making are likely to gain outsized growth.
The major growth opportunities, according to the MRFR report, include the use of AI-based analytics for better understanding of drug metabolism, development of consolidated platform-based pricing models for CRO services, and customized expansion in high-growth emerging markets through government biotech investment programs.
